Induction therapy with Zeposia improved key symptoms of concern to patients, including rectal bleeding and stool frequency as early as Week 2 in Phase 3 True North study
Maintenance treatment with Zeposia was associated with increased likelihood of corticosteroid-free remission in True North study
New data from pooled safety analysis of Zeposia shows a consistent safety profile
Data demonstrate commitment to understanding and helping improve outcomes in gastrointestinal immune-mediated diseases
https://finance.yahoo.com/news/bristol-myers-squibb-presents-data-153500737.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.